CarMax (KMX): 1st

Play Episode

7min

Proactive - Interviews for investors

Futura Medical CEO James Barder on Futura’s 2024 strong growth, maiden profit and 2025 plans

Futura Medical PLC CEO James Barder takes Proactive's Stephen Gunnion through the company’s 2024 financial performance, market expansion and product pipeline. Futura reported a strong year in 2024, with CEO Barder highlighting revenue of £14 million and a maiden profit of £1.3 million—or £3.3 million excluding non-cash items. Barder noted that Eroxon is now sold in over 15 countries and is expected to reach over 20 by the end of 2025. “2024 was a very good year for us,” he said. Barder emphasised the company’s commitment to supporting commercial partners and building momentum behind its flagship product, Eroxon. He explained that markets seeing the most success were those effectively targeting men under 60 with mild to moderate erectile dysfunction—Eroxon’s most responsive user group. The conversation also touched on upcoming products, including Eroxon Intense, a variant delivering a stronger sensory experience, and SD4000, a topical treatment for female sexual dysfunction. Barder noted that 87% of women in clinical trials for SD4000 wished to continue use post-study—an encouraging sign. Looking ahead, Barder said the company will continue expanding its presence, drive forward its pipeline, and focus on areas it can control, despite share price frustrations. For more interviews like this, visit Proactive’s YouTube channel. Don’t forget to like this video, subscribe to our channel, and hit the bell icon for updates. #FuturaMedical #Eroxon #EroxonIntense #SD4000 #ErectileDysfunction #FemaleHealth #PharmaNews #OTCProducts #HealthcareInnovation #BiotechUpdate

Proactive - Interviews for investors

Ocean Power Technologies expands global reach with reseller agreements in U.S. and Colombia

Ocean Power Technologies CEO Philipp Stratmann joined Steve Darling from Proactive to announce two significant reseller agreements, strengthening its commercial presence in both Latin America and the United States. The first agreement is with Elektron SAS, a Cartagena, Colombia-based company specializing in hydrographic and oceanographic instrumentation services. This partnership marks a major step forward in OPT’s expansion into Latin America. Elektron will provide sales, integration, and support services for OPT’s full suite of maritime solutions, including the WAM-V® Unmanned Surface Vehicles (USVs), the Next Generation PowerBuoy®, and the AI-powered Merrows™ platform. Importantly, the agreement includes a $4 million purchase commitment, underscoring strong regional demand and confidence in OPT’s technology. The collaboration leverages Elektron’s established network and technical expertise to help meet the growing need for advanced ocean monitoring and power systems across the region. In addition to the Latin American deal, OPT has signed another reseller agreement with Grava Hydrographic Solutions, a U.S.-based specialist in hydrographic and oceanographic equipment integration and services. Grava Hydro will help expand the availability and support of OPT’s WAM-V® USVs across the United States, positioning the technology for greater use in commercial, research, and government applications. #proactiveinvestors #oceanpowertechnologiesinc #nyseamerican #optt #PhillipStratmann, #USGovernmentContract, #OffshoreAutonomy, #MaritimeSecurity, #CommercialPlatforms, #GrowthStrategy, #BuoyBusiness, #VehicleBusiness, #InternationalExpansion, #ReadyToDeploy

Proactive - Interviews for investors

hVIVO CEO on record FY24 revenue & EBITDA as expansion strategy pays off

hVIVO PLC chief executive Yamin ‘Mo’ Khan takes Proactive's Stephen Gunnion through the company’s record-breaking financial performance in 2024, operational milestones and strategic outlook. hVIVO reported a 12% rise in revenue to just under £63 million, with an EBITDA margin of 26%. Khan highlighted this as a record margin for the company. He noted that, even excluding a one-off facility fee, the margin remained strong at 23%. The company also ended the year with £44 million in cash. Khan explained: “This is all been based on a record number of inoculations… we ran nine challenge trials and our largest field study to date.” He emphasised the company’s transformation, with a move to a purpose-built 50-bed human challenge facility in Canary Wharf, improvements in operational efficiency, and a major expansion of lab and outpatient capacity. Looking ahead, hVIVO is targeting £73 million in revenue for 2025, of which £70 million is already contracted. The company is also launching new challenge models, including Omicron and hMPV, and pursuing its first phase 3 human trial. Khan also discussed recent acquisitions—CRS in Germany and Cryostore in the UK—and confirmed continued dividend payments, with 0.2p per share set for June. For more interviews like this, visit Proactive's YouTube channel. Don’t forget to like the video, subscribe, and turn on notifications for future updates. #hVIVO #ClinicalTrials #HumanChallengeTrials #BiotechNews #EBITDA #RevenueGrowth #Biopharma #DrugDevelopment #CRSAcquisition #CryoStore #VaccineTrials #AntiviralResearch #LifeSciences #PharmaPipeline

Proactive - Interviews for investors

HANetf’s Tom Bailey on Future of European Defence UCITS ETF (ARMY)

HANetf head of research Tom Bailey talked with Proactive's Stephen Gunnion about the launch of the new Future of European Defence UCITS ETF (LSE:ARMY, XETRA:ARMY, EURONEXT:ARMY). Bailey explained the rationale behind launching a regionally focused fund, following the success of HANetf’s Global Future of Defence UCITS ETF (NATO). He said: “We think for many investors it kind of resonates with that whole theme of building up your defence sector via a European ETF with a European company.” Bailey noted that European defence spending rose by 11.7% between 2023 and 2024, outpacing global growth of 7.5%, with Germany’s own spend increasing 23%. This uptick is attributed to geopolitical shifts and the drive for strategic autonomy. Bailey highlighted a growing preference within Europe to source defence equipment domestically, reducing reliance on US firms, which currently account for around 60% of European defence procurement. He also pointed to political developments in the US, including recent tariff announcements and perceived isolationist policies, as reinforcing Europe's need for self-reliance in defence. The ARMY ETF is currently listed on the London Stock Exchange, Xetra (Germany), and Euronext Paris, with plans to launch in Italy. Bailey emphasised HANetf’s identity as a European company as central to the ETF’s appeal and alignment with strategic autonomy objectives. For more interviews like this, visit Proactive’s YouTube channel. Don’t forget to like this video, subscribe, and turn on notifications for the latest updates. #HANetf #ARMYETF #EuropeanDefence #DefenseSpending #StrategicAutonomy #ETFinvesting #TomBailey #NATOETF #EUstocks #MilitaryETF #EuropeanMarkets #Geopolitics #InvestorInsights #DefenseStocks

Followers	605
Posts	18345
Boards Moderated	0
Alias Born	02/23/2010

Volume:	1,100,348
Day Range:	63.63 - 64.725
Bid:
Ask:
Last Trade Time:	2:13:53 PM EDT
Total Trades:	19,396

Volume
Day Range:
Bid Price
Ask Price
Last Trade Time:

Boards:

Quotes:

Boards

News

Market Data

Markets

Discover

Discover

Boards:

Quotes:

KMX Detailed Quote

Recent KMX News

More KMX News

Boards:

Quotes:

Boards

News

Market Data

Markets

Discover

Discover

Boards:

Quotes:

Recent KMX News

Go Ad-Free